Intelligent Bio Solutions Inc Stock Price, News & Analysis

Intelligent Bio Solutions (NASDAQ: INBS) reported its fiscal Q2 2025 results, highlighting a 32.6% increase in gross profit and an 11-point rise in gross profit margin to 38.5%, driven by higher-margin cartridge sales. The company submitted its FDA 510(k) application in December 2024 and remains on track for U.S. market expansion in 2025.

Key financial metrics include Q2 revenue of $0.61 million, cash and equivalents of $2.24 million, and shareholders' equity of $4.20 million. The company secured 19 new accounts during the quarter, expanding its presence to over 400 active customers across 19 countries. However, revenue from sales decreased by $156,569 compared to the same quarter last year, and net loss increased to $2.25 million.

The company formed strategic partnerships with B2i Digital for investor marketing and Spirit Group for distribution in the Asia-Pacific region, while successfully completing method comparison and pharmacokinetic studies for its Intelligent Fingerprinting Drug Screening System.

Intelligent Bio Solutions (INBS) reported significant achievements in 2024 and outlined its 2025 U.S. expansion strategy. The company completed its FDA 510(k) pre-market notification in December 2024 for its Intelligent Fingerprinting Drug Testing Solution. Key financial highlights include 148% year-over-year revenue growth in fiscal 2024 and preliminary Q2 FY2024 revenue of $0.61 million, with improved gross profit margins reaching 38.5%.

The company currently serves over 400 accounts across 19 countries, reaching an estimated 1.4 million employees. Recent studies demonstrated approximately 94% accuracy in their drug testing system, with fingerprint sweat proving to be a reliable testing matrix. INBS is targeting the U.S. drug screening market, which represents 28% of the global market, with the total addressable market projected to reach $15 billion in the next six years.

Intelligent Bio Solutions (INBS) announces a new partnership with Avon Freight Group, implementing its fingerprint drug testing solution across three UK sites. This marks Avon's first in-house drug testing program, replacing their previous external oral swab testing method. INBS has expanded its presence to over 400 accounts across 19 countries.

The partnership highlights INBS's growth in the UK drug testing market, which is projected to reach $453 million by 2030. The company's non-invasive, rapid testing solution offers a more efficient and respectful alternative to traditional methods. Following its FDA 510(k) submission in December 2024, INBS is preparing for U.S. market expansion in 2025, positioning itself as a scalable, cost-effective leader in the drug testing industry.

Intelligent Bio Solutions (INBS) has announced preliminary unaudited financial results for fiscal Q2 and six months ended December 31, 2024. The company reported unaudited revenue of $0.61 million for Q2 and $1.48 million for the six-month period. Gross profit is expected to increase by 32.6% from $0.43 million to $0.57 million, with gross profit margin expanding to 38.5% from 27.7%.

The improved profitability is primarily driven by increased sales of high-margin cartridges used in the Intelligent Fingerprinting Drug Screening System. The company's total calendar year revenue grew 23% year-on-year, supported by a base of over 400 accounts. During Q2, INBS submitted a 510(k) premarket notification to the FDA for its drug screening system and formed strategic partnerships to expand its presence in the U.S. and international markets.

Intelligent Bio Solutions (INBS) announced a major upgrade to its Intelligent Fingerprinting Drug Screening System, introducing multilingual capabilities that will make the system accessible to over 4 billion users worldwide. The upgrade will support multiple languages across North and South America, Europe, Asia Pacific, and the Middle East.

The enhancement aims to improve usability in safety-critical industries such as construction, mining, manufacturing, transport, and logistics. This development aligns with the company's global expansion strategy, including its planned entry into the US market in 2025, following its FDA 510(k) submission in December 2024.

The company's non-invasive drug testing solution uses fingerprint sweat analysis to detect multiple substances simultaneously. INBS currently maintains presence in 19 countries, targeting the workplace drug testing market, which is projected to reach approximately $8 billion globally by 2030.

Intelligent Bio Solutions (INBS) announced that Quantum Traffic Management, a UK-based traffic management provider, has implemented INBS' Intelligent Fingerprinting Drug Testing Solution across its 10 nationwide sites. This transition from traditional saliva and urine testing to fingerprint sweat-based drug screening aims to enhance workplace testing efficiency and safety.

Quantum TM joins INBS's portfolio of more than 400 accounts across 19 countries. The fingerprint sweat-based system enables on-site drug screening without specialized staff or facilities, providing rapid results and improved operational efficiency. The company submitted an FDA 510(k) application in December 2024 and plans to enter the US market in 2025.

Intelligent Bio Solutions (INBS) has strengthened its presence in Europe and the Middle East through a partnership with IVY Diagnostics. The collaboration aims to expand the adoption of INBS' Intelligent Fingerprinting Drug Testing Solution, focusing on drug rehabilitation and law enforcement applications.

IVY Diagnostics has secured a tender in Italy to provide INBS' drug screening technology for rehabilitation programs. The solution is also undergoing trials with Turin's local police force for roadside screening. The European drug screening market is projected to reach $3.6 billion by 2030, while the Middle East and Africa market is expected to reach $432.7 million.

IVY Diagnostics serves as INBS' primary European contact, helping expand into Romania, Hungary, Slovakia, Austria, Scandinavia, UAE, Saudi Arabia, and Qatar through its distributor network.

Intelligent Bio Solutions (INBS) announced that Princebuild, a UK construction firm with seven sites, has adopted INBS' Intelligent Fingerprinting Drug Screening System, transitioning from saliva testing to fingerprint drug screening. The system offers a more streamlined, in-house solution prioritizing efficiency, accuracy, and employee privacy.

Princebuild joins INBS' portfolio of over 400 accounts across 19 countries, including notable construction companies like Mount Anvil, Hayfield Homes, Stonbury, MBP Structures, and PJ Hegarty & Sons U.K. The technology is used across multiple industries, including construction, mining, manufacturing, transport, law enforcement, and forensics.

Following its FDA 510(k) submission in December 2024, INBS plans to enter the US market in the first half of 2025, targeting expansion in the drug screening products market.

Intelligent Bio Solutions (INBS) has submitted a 510(k) premarket notification to the FDA for its Intelligent Fingerprinting Drug Screening System, a non-invasive drug testing solution. The system demonstrated 94.1% accuracy in performance studies and showed fingerprint sweat provides reliable drug detection comparable to blood tests at 95% confidence level.

The technology delivers results within 10 minutes through sweat collected from fingertips, targeting safety-critical industries like construction, mining, and transportation, as well as law enforcement and drug rehabilitation sectors. INBS aims to enter the US market in 2025, expanding its presence beyond existing international markets where the system has already proven cost-effective and operationally efficient.